Letrozole (Femara)
Aromatase inhibitor hormone therapy for ER-positive breast cancer in postmenopausal women.
What it targets
Estrogen receptor (ER) and hormone receptor (HR) pathway in postmenopausal breast cancer
Who it may help
Postmenopausal women with ER-positive or hormone receptor-positive breast cancer at any stage
Why testing matters
ER, PR, and HER2 testing by IHC; menopausal status assessment; DEXA scan for bone health
Which cancers can Letrozole treat?
| ER-positive early breast cancer (adjuvant) | After surgery in postmenopausal women with hormone receptor-positive early breast cancer to reduce the risk of recurrence. |
| Early breast cancer after tamoxifen (extended adjuvant) | Extended endocrine therapy in selected postmenopausal women who have completed a course of tamoxifen. |
| Locally advanced or metastatic breast cancer (first-line) | First-line treatment in postmenopausal women with hormone receptor-positive or hormone receptor-unknown advanced breast cancer. |
| Advanced breast cancer after anti-estrogen therapy | Later-line treatment when metastatic disease progresses after prior endocrine therapy such as tamoxifen. |
Who may benefit from Letrozole?
Letrozole is indicated for postmenopausal women with hormone receptor-positive breast cancer. Eligibility depends on hormone receptor status, menopausal status, disease stage, and prior treatment history.
- Postmenopausal women with confirmed ER-positive or HR-positive breast cancer.
- Patients needing adjuvant endocrine therapy after breast cancer surgery.
- Patients who have completed tamoxifen and need extended endocrine therapy.
- Patients with locally advanced or metastatic hormone receptor-positive breast cancer.
- Patients who may receive Letrozole alone or with a CDK4/6 inhibitor in metastatic disease.
- Patients whose oncologist confirms expected benefit outweighs risks including bone loss and joint pain.
- Premenopausal women only under specialist supervision with ovarian suppression — not the standard indication.
How does Letrozole work?
- Blocking the aromatase enzyme
- Lowering circulating estrogen
- Starving hormone receptor-positive cancer cells
- Reducing recurrence risk in early disease
Tests needed before and during Letrozole treatment
Several tests are needed to confirm eligibility for Letrozole, establish a treatment baseline, and monitor safety during therapy.
| ER, PR, and HER2 testing | Immunohistochemistry (IHC) and/or in situ hybridisation to confirm hormone receptor-positive status — required before Letrozole is prescribed. |
| Biopsy and histopathology | Tissue confirmation of breast cancer type, grade, and receptor status. |
| Menopausal status assessment | FSH and estradiol levels may be checked to confirm postmenopausal status before starting Letrozole. |
| Bone density (DEXA scan) | Baseline bone mineral density assessment recommended, especially for long-term therapy, to guide bone health management. |
| Liver and kidney function tests | Baseline liver and renal function when clinically indicated, as Letrozole is metabolised hepatically. |
| Lipid profile | Baseline cholesterol and lipid panel in selected patients, as Letrozole can affect cholesterol levels. |
| Staging imaging | CT scan, bone scan, or other imaging to assess disease stage or confirm metastatic involvement before starting treatment. |
| Pregnancy test | Required if there is any possibility of pregnancy, as Letrozole is teratogenic and must not be used during pregnancy. |
How is Letrozole given?
Letrozole is taken as an oral tablet at home. No infusion or injection is required. The standard dose is 2.5 mg once daily, as specified in the FDA label for Femara.
| Standard dose | 2.5 mg orally once daily, as specified in the FDA-approved labelling. |
| Adjuvant / extended adjuvant setting | 2.5 mg once daily, typically for five years or as directed by the oncologist. |
| Advanced or metastatic setting | 2.5 mg once daily, continued as long as the drug is providing benefit and side effects are manageable. |
| How to take | Can be taken with or without food. Swallow the tablet whole with water. |
| Timing | Take at the same time each day to maintain consistent drug levels. A daily routine helps with adherence. |
| Missed dose | Take the missed dose on the same day if remembered. If the next day has already started, skip and resume normally. Do not double up. |
| Duration | In early breast cancer, typically taken for five years or longer as adjuvant therapy. In metastatic disease, continued until progression or intolerable side effects. Your oncologist determines duration. |
Clinical evidence and benefits of Letrozole
Letrozole has been evaluated in multiple large randomised trials establishing its role in early and advanced hormone receptor-positive breast cancer.
| Adjuvant early breast cancer (BIG 1-98 trial) | In the BIG 1-98 trial, Letrozole significantly reduced the risk of recurrence compared with tamoxifen as adjuvant therapy in postmenopausal women with HR-positive early breast cancer. |
| Extended adjuvant after tamoxifen (MA.17 trial) | The MA.17 trial showed that Letrozole given after five years of tamoxifen substantially extended disease-free survival compared with placebo in postmenopausal women. |
| First-line metastatic breast cancer | As first-line therapy in advanced HR-positive disease, Letrozole demonstrated significantly longer progression-free survival compared with tamoxifen in postmenopausal women. |
| Combination with CDK4/6 inhibitors | Letrozole plus CDK4/6 inhibitors (such as palbociclib, ribociclib, or abemaciclib) substantially prolongs progression-free survival in advanced HR-positive/HER2-negative breast cancer compared with Letrozole alone. |
| Oral and outpatient treatment | As an oral tablet taken at home, Letrozole avoids the need for hospital infusions, which can improve day-to-day quality of life for patients on long-term endocrine therapy. |
| Established safety profile | Letrozole has been in clinical use for over two decades with a well-understood side effect profile and established monitoring guidelines for long-term management. |
Individual responses vary. These represent findings from published clinical trials and are not a guarantee of outcome for any individual patient.
Side effects of Letrozole
Letrozole is not chemotherapy and does not cause hair loss or severe nausea in most patients. Its side effects are primarily related to low estrogen levels and resemble menopausal symptoms. Most are manageable with monitoring and supportive care.
| Hot flashes | Very common; caused by reduced estrogen. Non-hormonal management strategies are available. |
| Joint pain and stiffness | Common; often affects hands, wrists, knees, and hips. Exercise, physiotherapy, and dose review can help. |
| Muscle pain | Common; usually mild to moderate. Regular gentle exercise may reduce severity. |
| Fatigue | Common; particularly in the first months. Often improves over time. |
| Increased sweating | Common; linked to low estrogen levels. Lightweight clothing and cool environments may help. |
| Nausea | Less common; typically mild. Taking Letrozole with food may reduce nausea. |
| Headache and dizziness | Reported in some patients; usually mild. Report persistent or severe episodes to your doctor. |
| Hair thinning | Can occur but is generally less severe than chemotherapy-related hair loss. |
| Vaginal dryness | Common due to low estrogen. Non-hormonal vaginal moisturisers may help; discuss with oncologist. |
| Mood changes | Some patients report low mood or mood fluctuations. Discuss with your oncologist if significantly affecting daily life. |
| Bone thinning (osteoporosis) | Reduced bone mineral density is a known long-term risk. DEXA monitoring and bone health support are important. |
| Cholesterol changes | Letrozole can raise LDL cholesterol in some patients. Lipid monitoring may be recommended. |
Contact your doctor immediately if you develop:
- New or worsening bone pain, especially if severe or sudden.
- Fracture after minor injury or without obvious cause.
- Chest pain, severe shortness of breath, or leg swelling.
- Signs of allergic reaction: rash, swelling of face or throat, difficulty breathing.
- Severe dizziness, fainting, or sudden vision changes.
- Symptoms that significantly affect your ability to function day to day.
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medicines, supplements, and herbal products you are taking before starting Letrozole.
- Do not use estrogen-containing hormone replacement therapy — it directly opposes the mechanism of Letrozole.
- CYP enzyme inducers such as rifampicin and carbamazepine may reduce Letrozole levels; discuss with your oncologist.
- Tamoxifen used simultaneously with Letrozole may reduce Letrozole plasma levels — sequential use is preferred.
- Letrozole is teratogenic and must not be used during pregnancy. Effective contraception is required for women of childbearing potential.
- Breastfeeding should be avoided during Letrozole treatment.
- Tell your doctor if you have osteoporosis, low bone density, or a history of fractures — bone health management plan is needed.
- Tell your doctor if you have liver disease — Letrozole is hepatically metabolised and clearance may be reduced.
- Tell your doctor if you have high cholesterol or heart disease — lipid monitoring may be required.
- Tell your doctor if you take calcium or vitamin D supplements, bisphosphonates, or any other bone medicines.
Letrozole combination treatments
Letrozole can be used alone or in combination with targeted therapies depending on disease stage, prior treatment history, and oncologist recommendation.
| Letrozole + CDK4/6 inhibitor (palbociclib) | First-line standard of care in HR-positive/HER2-negative advanced breast cancer. Substantially prolongs progression-free survival versus Letrozole alone. PALOMA-2 trial basis. |
| Letrozole + CDK4/6 inhibitor (ribociclib) | First-line combination supported by MONALEESA-2 trial data. Also showed overall survival benefit in HR-positive/HER2-negative advanced breast cancer. |
| Letrozole + CDK4/6 inhibitor (abemaciclib) | Another approved first-line combination option in HR-positive/HER2-negative advanced breast cancer. Selection among CDK4/6 inhibitors depends on side effect profile and oncologist preference. |
| Letrozole alone (adjuvant) | Used as monotherapy in adjuvant and extended adjuvant settings for early breast cancer in postmenopausal women. |
| Letrozole with ovarian suppression | Used in premenopausal women only under specialist supervision with ovarian function suppression to achieve a postmenopausal endocrine environment — not the standard indication. |
| Switching options if Letrozole fails | Fulvestrant (selective estrogen receptor degrader), exemestane, anastrozole, or switching to a non-aromatase inhibitor endocrine backbone in combination with PI3K/AKT/mTOR pathway drugs. |
If Letrozole stops working
Resistance to Letrozole can develop over time. Understanding the mechanism guides next treatment decisions.
| ESR1 mutations | Acquired mutations in the estrogen receptor gene (ESR1) are the most common resistance mechanism in metastatic breast cancer after aromatase inhibitor therapy. Liquid biopsy or tumour NGS can detect these. |
| CDK4/6 pathway activation | Upregulation of cell cycle kinases can allow HR-positive cells to bypass endocrine blockade. CDK4/6 inhibitors are added or switched to address this mechanism. |
| PI3K/AKT/mTOR pathway activation | Activation of downstream survival pathways can drive resistance. Everolimus plus exemestane and alpelisib plus fulvestrant are options depending on PIK3CA mutation status. |
| HER2 amplification or overexpression | Some tumours can acquire or reveal HER2 amplification at progression — repeat biomarker testing is important to detect this and guide therapy. |
| Next-line endocrine options | Fulvestrant, elacestrant (oral SERD for ESR1-mutated disease), and other SERDs are options after aromatase inhibitor failure, depending on mutation status and prior treatment. |
| Chemotherapy | When endocrine therapy options are exhausted, cytotoxic chemotherapy or antibody-drug conjugates may be considered based on disease burden and fitness. |
Cost of Letrozole by country
Generic Letrozole is widely available and considerably more affordable than newer targeted therapies. Total treatment cost increases if combination with a CDK4/6 inhibitor, imaging, or bone monitoring is required.
| India | Generic Letrozole is available from multiple Indian manufacturers at very low monthly cost. Femara (branded) is also available at higher price. No major patient assistance programme required for generics. |
| USA | Generic Letrozole is available in the USA at low monthly cost through major pharmacies. Branded Femara is substantially more expensive. Novartis offers patient assistance programmes for eligible patients. |
| UK / Europe | Letrozole is fully covered under NHS in the UK and national insurance systems across most EU countries for approved indications. Patient cost is typically nil or minimal co-payment. |
| China | Letrozole is approved by the NMPA (National Medical Products Administration) and available at major cancer hospitals. Generic versions are available through the national reimbursement system. |
| UAE / Gulf | Letrozole is available through major hospital pharmacies and some community pharmacies. Insurance coverage varies by plan and employer. Self-pay cost is moderate for generics. |
Availability of Letrozole globally
Letrozole is one of the most widely available hormone therapy drugs globally. It holds FDA, EMA, and NMPA approvals, and generic versions are accessible in most major markets.
India
Letrozole is widely available in India from multiple domestic manufacturers as a low-cost generic. Available at cancer hospitals and retail pharmacies. Prescription required. No supply shortage reported.
USA
Generic Letrozole is available at most pharmacies in the USA at low cost. Branded Femara is available with a prescription. Patient assistance programmes available from Novartis for eligible uninsured patients.
UK
Letrozole is available on the NHS for approved breast cancer indications with no patient cost. Generic supply is well established. Available in community pharmacies with oncologist prescription.
China
Letrozole (Femara and generic) is approved by the NMPA and available at major cancer centres and hospitals. Listed on the National Reimbursement Drug List (NRDL) for eligible patients.
Germany / EU
Letrozole is covered by statutory health insurance in Germany and most EU countries for approved indications. Generic availability is excellent throughout the EU.
Letrozole in current and ongoing clinical trials
Letrozole continues to be evaluated in clinical trials, primarily as part of combination regimens targeting resistance mechanisms and optimising treatment duration in hormone receptor-positive breast cancer.
| CDK4/6 inhibitor combinations | Ongoing studies evaluating optimal sequencing, duration, and patient selection for Letrozole plus CDK4/6 inhibitor combinations in both advanced and early-stage HR-positive breast cancer. |
| PI3K/AKT/mTOR pathway combinations | Trials investigating Letrozole with alpelisib, everolimus, or AKT inhibitors in patients with PI3K-pathway alterations at baseline or progression. |
| Novel SERD combinations | Studies combining Letrozole or other aromatase inhibitors with oral SERDs (selective estrogen receptor degraders) to provide dual estrogen pathway suppression. |
| Early breast cancer duration and de-escalation | Trials examining optimal adjuvant endocrine therapy duration, including whether shorter courses are sufficient for lower-risk patients and who benefits from extended therapy beyond 5 years. |
| Biomarker-driven treatment selection | Trials using liquid biopsy and circulating tumour DNA to detect early resistance mutations such as ESR1 and guide early switching from Letrozole to alternative endocrine therapy. |
Your treatment journey with Letrozole
Breast cancer diagnosis
Biopsy and receptor testing
Menopausal status assessment
Staging and treatment planning
Baseline safety checks
Starting Letrozole
Monitoring and side effect management
Treatment adjustment or next steps
Questions to ask your oncologist about Letrozole
- Is my breast cancer confirmed as ER-positive or hormone receptor-positive?
- Am I postmenopausal, and is Letrozole the right endocrine therapy for me?
- How long do I need to take Letrozole?
- Should I take Letrozole alone or with another medicine?
- How will we monitor my bone health during treatment?
- What should I do about joint pain and stiffness?
- What is the expected cost and how do I access generic Letrozole?
- What are my options if Letrozole stops working?
How CancerFax supports Letrozole patients
CancerFax helps patients and families navigate Letrozole treatment, breast cancer biomarker testing, second opinions, and cross-border care options.
| Medical report review | Upload your biopsy, ER/PR/HER2 pathology, DEXA scan, or imaging reports — our oncology team reviews and explains what they mean for Letrozole eligibility and treatment planning. |
| Specialist connection | We connect patients with breast oncologists experienced in hormone receptor-positive breast cancer and aromatase inhibitor management in India, China, and internationally. |
| Second opinion for advanced disease | If your cancer has progressed on Letrozole, CancerFax arranges a specialist second opinion focused on next-line options including CDK4/6 combinations, SERDs, and advanced breast cancer trials. |
| Generic access guidance | We help patients identify legitimate generic Letrozole sources in India and other markets, including cost navigation and pharmacy guidance for cross-border treatment. |
| China treatment access | CancerFax coordinates access to advanced breast cancer treatment options in China, including novel combinations and clinical trial opportunities not available in other countries. |
| Treatment journey support | From biomarker testing to long-term monitoring, CancerFax helps families understand each stage of the Letrozole treatment journey and what to expect at each step. |
Frequently asked questions about Letrozole
Common questions from patients and caregivers
No. Letrozole is a hormone therapy, not chemotherapy. It is an aromatase inhibitor that lowers estrogen levels in postmenopausal women, which helps slow or stop the growth of estrogen receptor-positive breast cancer cells. It does not kill cells the way chemotherapy does, and it generally causes fewer and different side effects than chemotherapy.
Letrozole begins lowering estrogen levels within days of starting treatment. However, its effect on cancer is measured over months and years — in early breast cancer, it is typically taken for five years or longer to reduce recurrence risk. In metastatic breast cancer, response is assessed through scans and clinical evaluation over the first few months of treatment.
Letrozole is approved for postmenopausal women. In premenopausal women, it is only used under specialist supervision in combination with ovarian suppression to achieve a postmenopausal hormone environment. If you are premenopausal, discuss with your oncologist whether ovarian suppression plus an aromatase inhibitor is appropriate for your situation.
Letrozole lowers estrogen levels, and estrogen plays an important role in maintaining bone mineral density. Long-term use can lead to bone thinning and an increased risk of fractures. Your oncologist will typically recommend a baseline DEXA scan, follow-up bone density monitoring, and may prescribe calcium, vitamin D, and sometimes bone-strengthening medicines such as bisphosphonates.
Take the missed dose on the same day as soon as you remember. If it is already the following day, skip the missed dose and take the next one at the usual time — do not take two doses at once. Occasional missed doses are unlikely to significantly affect treatment, but consistent missed doses may reduce effectiveness. Always discuss adherence with your oncologist.
No. Estrogen-containing hormone replacement therapy should not be taken while you are on Letrozole, because it works against the treatment's goal of lowering estrogen. If menopausal symptoms such as hot flashes are significantly affecting your quality of life, ask your oncologist about non-hormonal management options that are safe to use alongside Letrozole.
If breast cancer progresses while on Letrozole, your oncologist may recommend repeat biopsy or liquid biopsy to check for resistance mutations such as ESR1, reassess ER/PR/HER2 status, and consider switching to another endocrine therapy, adding or changing targeted therapy such as a CDK4/6 inhibitor or PI3K pathway drug, or chemotherapy if endocrine options are exhausted. A second opinion is often valuable at this point.